Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3151 |
Name | skin squamous cell carcinoma |
Definition | A skin carcinoma that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin carcinoma skin squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
HRAS Q61L | PLX7904 | skin squamous cell carcinoma | no benefit | detail... |
MAP2K1 E203K PIK3CA amp | Metformin + Trametinib | skin squamous cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02324608 | Phase I | Cetuximab | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | Active, not recruiting | USA | 0 |
NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02760498 | Phase II | Cemiplimab | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Completed | USA | ITA | FRA | ESP | DEU | AUS | 2 |
NCT02964559 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | Active, not recruiting | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03108131 | Phase II | Atezolizumab + Cobimetinib | Cobimetinib and Atezolizumab in Advanced Rare Tumors | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | FRA | ESP | AUS | 6 |
NCT03284424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) | Completed | USA | GBR | FRA | ESP | DEU | CAN | AUS | 3 |
NCT03524326 | Phase I | Cetuximab + Lenvatinib | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
NCT03666325 | Phase II | Pembrolizumab Cetuximab + Pembrolizumab | Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) | Unknown status | ITA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03833167 | Phase III | Pembrolizumab | Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 16 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | DEU | BEL | 1 |
NCT03889912 | Phase I | Cemiplimab | Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Active, not recruiting | USA | ESP | CAN | BEL | 0 |
NCT03901573 | Phase Ib/II | Atezolizumab + NT-I7 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03944941 | Phase II | Avelumab Avelumab + Cetuximab | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | Recruiting | USA | 0 |
NCT03969004 | Phase III | Cemiplimab | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT04050436 | Phase II | Cemiplimab + RP1 RP1 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04105543 | Phase I | CLR 131 | CLR 131 Combined With Radiation for Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT04154943 | Phase II | Cemiplimab | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | DEU | AUS | 0 |
NCT04160065 | Phase I | IFx-Hu2.0 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC | Recruiting | USA | 0 |
NCT04163952 | Phase I | Panitumumab + Talimogene laherparepvec | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | Active, not recruiting | USA | 0 |
NCT04204837 | Phase II | Nivolumab + Relatlimab Nivolumab | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | Recruiting | AUT | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04293679 | Phase Ib/II | Cotsiranib | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | Completed | USA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04305795 | Phase Ib/II | ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04315701 | Phase II | Cemiplimab | A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | Recruiting | USA | 0 |
NCT04339062 | Phase I | Cemiplimab Cemiplimab + Everolimus + Prednisone Cemiplimab + Prednisone + Sirolimus | Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC) | Active, not recruiting | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04428671 | Phase I | Cemiplimab | Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer | Recruiting | USA | 0 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04502888 | Phase I | SL-172154 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Terminated | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Completed | USA | ITA | FRA | ESP | DEU | CAN | 8 |
NCT04632433 | Phase II | Cemiplimab | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | Active, not recruiting | ITA | 0 |
NCT04710498 | Phase II | Atezolizumab | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04807777 | Phase II | Ruxolitinib | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04808999 | Phase II | Pembrolizumab | Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | Recruiting | USA | 0 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04913220 | Phase Ib/II | Cemiplimab + THOR-707 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUS | 4 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Recruiting | USA | AUS | 0 |
NCT04925713 | Phase I | IFx-Hu2.0 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | Completed | USA | 0 |
NCT04975152 | Phase I | Cemiplimab | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04985825 | Phase II | Imgatuzumab | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE) | Withdrawn | 0 | |
NCT05025813 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) | Recruiting | AUS | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Recruiting | USA | GBR | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05070403 | Phase II | Afatinib | Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05085496 | Phase I | Atezolizumab | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Recruiting | FRA | 1 |
NCT05220748 | Phase I | Pembrolizumab + RM-1995 RM-1995 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | Withdrawn | 0 | |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05329792 | Phase II | Daromun | L19IL2/L19TNF in Skin Cancer Patients | Recruiting | ITA | FRA | ESP | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05574101 | Phase II | Cemiplimab | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | Recruiting | USA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Recruiting | ESP | BEL | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05729139 | Phase I | Cemiplimab + Peg-interferon alfa-2a | Cemiplimab/Peg-Interferon-a in Advanced CSCC | Withdrawn | USA | 0 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Recruiting | USA | 0 |
NCT05878288 | Phase II | Cemiplimab | Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN) | Recruiting | AUS | 0 |
NCT05888844 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | FRA | ESP | CAN | AUS | 14 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 | Recruiting | USA | ESP | AUS | 0 |
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |
NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Recruiting | USA | CAN | AUS | 1 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |